摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-((2)-azabicyclo[2.2.1]heptan-2-yl)ethan-1-amine | 878155-47-6

中文名称
——
中文别名
——
英文名称
2-((2)-azabicyclo[2.2.1]heptan-2-yl)ethan-1-amine
英文别名
2-(2-Azabicyclo[2.2.1]heptan-2-yl)ethanamine
2-((2)-azabicyclo[2.2.1]heptan-2-yl)ethan-1-amine化学式
CAS
878155-47-6
化学式
C8H16N2
mdl
——
分子量
140.228
InChiKey
CLPVUDZYVCDMBZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    217.2±8.0 °C(Predicted)
  • 密度:
    1.019±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    10
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    29.3
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • Pyrimidines as PLK inhibitors
    申请人:STADTMUELLER Heinz
    公开号:US20110086842A1
    公开(公告)日:2011-04-14
    The present invention encompasses compounds of general formula (1), wherein A, W, X, Y, Z, Ra, Rb, Rc, R1 and R3 are defined as in claim 1 , which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    本发明涵盖了一般式(1)的化合物,其中A、W、X、Y、Z、Ra、Rb、Rc、R1和R3如权利要求1所定义,适用于治疗以细胞过度或异常增殖为特征的疾病,并且用于制备具有上述特性的药物组合物。
  • [EN] INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PROTÉINE ANOCTAMINE 6 ET LEURS UTILISATIONS
    申请人:ILDONG PHARMACEUTICAL CO LTD
    公开号:WO2022157686A1
    公开(公告)日:2022-07-28
    The present invention relates to a new compound that can inhibit an anoctamin 6 protein, a composition comprising the compound, a method for preparing the compound, and a method for using the compound or composition.
    本发明涉及一种新化合物,可以抑制anoctamin 6蛋白质,包括该化合物的组合物,制备该化合物的方法,以及使用该化合物或组合物的方法。
  • Structure–Activity Relationships of 4-Position Diamine Quinoline Methanols as Intermittent Preventative Treatment (IPT) against <i>Plasmodium falciparum</i>
    作者:Erin Milner、Sean Gardner、Jay Moon、Kristina Grauer、Jennifer Auschwitz、Ian Bathurst、Diana Caridha、Lucia Gerena、Montip Gettayacamin、Jacob Johnson、Michael Kozar、Patricia Lee、Susan Leed、Qigui Li、William McCalmont、Victor Melendez、Norma Roncal、Richard Sciotti、Bryan Smith、Jason Sousa、Anchalee Tungtaeng、Peter Wipf、Geoffrey Dow
    DOI:10.1021/jm200647u
    日期:2011.9.22
    A library of diamine quinoline methanols were designed based on the mefloquine scaffold. The systematic variation of the 4-position amino alcohol side chain led to analogues that maintained potency while reducing accumulation in the central nervous system (CNS). Although the mechanism of action remains elusive, these data indicate that the 4-position side chain is critical for activity and that potency (as measured by IC(90)) does not correlate with accumulation in the CNS. A new lead compound, (S)-1-(2,8-bis(trifluoromethyl)quinolin-4-yl)-2-(2-(cyclopropylamino)ethylamino)ethanol (WR621308), was identified with single dose efficacy and substantially lower permeability across MDCK cell monolayers than mefloquine. This compound could be appropriate for intermittent preventative treatment (IPTx) indications or other malaria treatments currently approved for mefloquine.
  • 2,4-DI(AMINOPHENYL)PYRIMIDINE ALS PLK INHIBITOREN
    申请人:Boehringer Ingelheim International GmbH
    公开号:EP1781640B1
    公开(公告)日:2015-01-07
  • US7521457B2
    申请人:——
    公开号:US7521457B2
    公开(公告)日:2009-04-21
查看更多